SRPT Share Price

Open 30.76 Change Price %
High 30.89 1 Day -0.84 -2.72
Low 29.40 1 Week -4.63 -13.37
Close 30.01 1 Month -4.71 -13.57
Volume 2127876 1 Year 8.82 41.62
52 Week High 63.73
52 Week Low 14.83
SRPT Important Levels
Resistance 2 31.39
Resistance 1 30.82
Pivot 30.10
Support 1 29.20
Support 2 28.63
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
DCTH 0.02 0.00%
SUSQ 14.20 -0.77%
ASTI 0.00 0.00%
SIRI 5.29 3.32%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
NIHD 0.74 39.62%
NIHD 0.74 39.62%
WRES 0.09 28.57%
CGEI 0.28 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
AEZS 1.18 22.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

Sarepta Therapeutics, Inc. (NASDAQ: SRPT)

SRPT Technical Analysis 4
As on 26th May 2017 SRPT Share Price closed @ 30.01 and we RECOMMEND Sell for LONG-TERM with Stoploss of 33.24 & Strong Sell for SHORT-TERM with Stoploss of 31.87 we also expect STOCK to react on Following IMPORTANT LEVELS.
SRPT Target for May
1st Target up-side 42.36
2nd Target up-side 46.64
3rd Target up-side 50.92
1st Target down-side 30.16
2nd Target down-side 25.88
3rd Target down-side 21.6
SRPT Other Details
Segment EQ
Market Capital 539801792.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.sareptatherapeutics.com
SRPT Address
SRPT
215 First Street
Suite 415
Cambridge, MA 02142
United States
Phone: 857-242-3700
SRPT Latest News
Interactive Technical Analysis Chart Sarepta Therapeutics, Inc. ( SRPT NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Sarepta Therapeutics, Inc.
SRPT Business Profile
Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. Its product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. It is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). It initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.